Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol and melitracen is a fixed-dose combination medication containing a neuroleptic (flupentixol) and a tricyclic antidepressant (melitracen). It is typically used for conditions involving anxiety and depression.
## Primary Indications
* Anxiety disorders
* Depression
## Adult Dosing
* **Typical Starting Dose:** 1 tablet (flupentixol 0.5 mg / melitracen 10 mg) twice daily, taken orally in the morning and evening.
* **Maintenance Dose:** The dose may be increased to 2 tablets twice daily if necessary.
* **Maximum Dose:** Not explicitly defined in standard references, but escalation should be guided by clinical response and tolerability.
## Pediatric Dosing
* Safety and efficacy in pediatric patients have not been established. Dosing in this population is not recommended.
## Dose Adjustments
* **Hepatic Impairment:** Caution is advised. Dose reduction may be necessary. Specific guidelines vary; consult local protocols.
* **Renal Impairment:** No specific dose adjustments are typically outlined, but caution is warranted, especially in severe impairment.
## Contraindications
* Known hypersensitivity to flupentixol, melitracen, or any excipients.
* Severe central nervous system (CNS) depression.
* Circulatory collapse.
* Phaeochromocytoma.
* Concomitant use with MAOIs or within 14 days of discontinuing MAOIs.
## Adverse Effects
* **Common:** Sedation, dizziness, dry mouth, constipation, blurred vision, headache, fatigue.
* **Less Common/Serious:** Extrapyramidal symptoms (akathisia, dystonia, parkinsonism), tardive dyskinesia (with prolonged use), anticholinergic effects (urinary retention, tachycardia), orthostatic hypotension, cardiovascular effects (arrhythmias, ECG changes), increased seizure risk, withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **MAOIs:** Increased risk of hypertensive crisis or serotonin syndrome.
* **CNS Depressants (e.g., alcohol, sedatives, hypnotics, opioids):** Additive CNS depression.
* **Anticholinergic Agents:** Potentiated anticholinergic effects.
* **Antihypertensives:** Flupentixol may reduce the effect of some antihypertensives.
* **QTc Prolonging Agents:** Increased risk of QTc interval prolongation and torsades de pointes.
## Monitoring
* **Baseline:** Assess cardiovascular status, liver function, and history of seizures.
* **Ongoing:** Monitor for therapeutic efficacy, adverse effects (especially CNS and cardiovascular), and signs of withdrawal. Consider ECG monitoring in patients with cardiac risk factors.
## Clinical Pearls
* This combination is often used for patients experiencing symptoms of both anxiety and depression concurrently.
* Start with a low dose and titrate slowly based on patient response and tolerability.
* Advise patients to avoid alcohol due to enhanced CNS depressant effects.
* Inform patients about potential side effects like sedation and anticholinergic effects, and counsel on managing them (e.g., avoiding driving until they know how the medication affects them).
* Abrupt discontinuation should be avoided; tapering is recommended.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and local guidelines before making any treatment decisions.*
